Jenburkt Pharmaceuticals Limited
Bombay Stock ExchangeTotal Valuation
Jenburkt Pharmaceuticals Limited carries a market capitalization of 4.87B, placing it among publicly traded companies globally. Its enterprise value stands at 6.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.87B |
| Enterprise Value | 6.06B |
Valuation Ratios
Jenburkt Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 18.67.
| PE Ratio | 18.67 |
| PS Ratio | 3.91 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Jenburkt Pharmaceuticals Limited trades at an EV/EBITDA multiple of 16.31 and an EV/FCF ratio of 1,836.05. The EV/Sales ratio of 3.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.31 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.91 |
| EV / EBITDA | 16.31 |
| EV / EBIT | 16.31 |
| EV / FCF | 1,836.05 |
Financial Position
Jenburkt Pharmaceuticals Limited maintains a current ratio of 8.89, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.61, indicating elevated leverage, while an interest coverage ratio of 82.90 demonstrates strong ability to service its debt obligations.
| Current Ratio | 8.89 |
| Quick Ratio | 5.64 |
| Debt / Equity | 3.61 |
| Debt / EBITDA | N/A |
| Interest Coverage | 82.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 563.91 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Jenburkt Pharmaceuticals Limited has paid 116.17M in income taxes, reflecting an effective tax rate of 26.37.
| Income Tax | 116.17M |
| Effective Tax Rate | 26.37 |
Stock Price Statistics
Jenburkt Pharmaceuticals Limited's stock has declined approximately -20.49656% over the past 52 weeks. The 50-day moving average sits at 1,137.57, while the 200-day moving average is 1,095.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -20.49656% |
| 50-Day Moving Average | 1,137.57 |
| 200-Day Moving Average | 1,095.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Jenburkt Pharmaceuticals Limited generated 1.55B in revenue and converted that into 324.36M in net income, yielding earnings per share of 73.50. EBITDA reached 371.29M, while operating income came in at 371.29M.
| Revenue | 1.55B |
| Gross Profit | 1.25B |
| Operating Income | 371.29M |
| Pretax Income | 440.54M |
| Net Income | 324.36M |
| EBITDA | 371.29M |
| EBIT | 371.29M |
| Earnings Per Share (EPS) | 73.50 |
Margins
Jenburkt Pharmaceuticals Limited operates with a gross margin of 80.68, reflecting its pricing power and cost economics. The operating margin of 24.00 and net profit margin of 20.97 provide insight into operational efficiency.
| Gross Margin | 80.68 |
| Operating Margin | 24.00 |
| Pretax Margin | 28.48 |
| Profit Margin | 20.97 |
| EBITDA Margin | 24.00 |
Scores
Jenburkt Pharmaceuticals Limited posts an Altman Z-Score of 27.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 27.66 |